NCT06943755: An ongoing trial by Exelixis
This trial is ongoing. It must report results 4 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06943755 |
|---|---|
| Title | A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 21, 2025 |
| Completion date | June 30, 2029 |
| Required reporting date | June 30, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |